Cargando…

Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer

OBJECTIVE: To assess retrospectively the feasibility of intraoperative intraperitoneal (IP) chemotherapy with cisplatin in epithelial ovarian cancer. METHODS: IP chemotherapy during optimal staging surgery was performed in 10 patients who were diagnosed with primary epithelial ovarian cancers betwee...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Myung Joo, Jung, Yong Wook, Seong, Seok Ju, Yoon, Bo Sung, Kim, Mi La, Joo, Won Deok, Song, Tae Jong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Gynecologic Oncology and Colposcopy 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325355/
https://www.ncbi.nlm.nih.gov/pubmed/22523624
http://dx.doi.org/10.3802/jgo.2012.23.2.91
_version_ 1782229428225441792
author Kim, Myung Joo
Jung, Yong Wook
Seong, Seok Ju
Yoon, Bo Sung
Kim, Mi La
Joo, Won Deok
Song, Tae Jong
author_facet Kim, Myung Joo
Jung, Yong Wook
Seong, Seok Ju
Yoon, Bo Sung
Kim, Mi La
Joo, Won Deok
Song, Tae Jong
author_sort Kim, Myung Joo
collection PubMed
description OBJECTIVE: To assess retrospectively the feasibility of intraoperative intraperitoneal (IP) chemotherapy with cisplatin in epithelial ovarian cancer. METHODS: IP chemotherapy during optimal staging surgery was performed in 10 patients who were diagnosed with primary epithelial ovarian cancers between April 2008 and February 2011. Cisplatin (70 mg/m(2) in 1 L normal saline solution) was administered in the abdominal cavity for 24 hours postoperatively and then adjuvant chemotherapy was started 2-4 weeks after surgery. Perioperative toxicity of the combined treatment was evaluated until the initiation of postoperative adjuvant chemotherapy. RESULTS: A total of 23 adverse events were observed in 9 of 10 patients (grade 1, 7; grade 2, 13; grade 3, 3; grade 4, 0). In descending order of frequency, adverse events affected the gastrointestinal system (n=14), hematologic system (n=6), pulmonary system (n=2), and genito-urinary system (n=1). The adverse events did not affect adjuvant systemic chemotherapy schedules. One patient experienced disease recurrence in the liver 16 months after surgery. The remaining 9 patients have been well controlled by chemotherapy and/or observation during the follow-up period of 4 to 39 months after surgery. CONCLUSION: Intraoperative IP chemotherapy with cisplatin during surgical procedures is considered feasible for the treatment of primary epithelial ovarian cancer. Further studies, including long-term, prospective and comparative trials, are needed to validate the efficacy of this combined therapy.
format Online
Article
Text
id pubmed-3325355
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Korean Society of Gynecologic Oncology and Colposcopy
record_format MEDLINE/PubMed
spelling pubmed-33253552012-04-20 Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer Kim, Myung Joo Jung, Yong Wook Seong, Seok Ju Yoon, Bo Sung Kim, Mi La Joo, Won Deok Song, Tae Jong J Gynecol Oncol Original Article OBJECTIVE: To assess retrospectively the feasibility of intraoperative intraperitoneal (IP) chemotherapy with cisplatin in epithelial ovarian cancer. METHODS: IP chemotherapy during optimal staging surgery was performed in 10 patients who were diagnosed with primary epithelial ovarian cancers between April 2008 and February 2011. Cisplatin (70 mg/m(2) in 1 L normal saline solution) was administered in the abdominal cavity for 24 hours postoperatively and then adjuvant chemotherapy was started 2-4 weeks after surgery. Perioperative toxicity of the combined treatment was evaluated until the initiation of postoperative adjuvant chemotherapy. RESULTS: A total of 23 adverse events were observed in 9 of 10 patients (grade 1, 7; grade 2, 13; grade 3, 3; grade 4, 0). In descending order of frequency, adverse events affected the gastrointestinal system (n=14), hematologic system (n=6), pulmonary system (n=2), and genito-urinary system (n=1). The adverse events did not affect adjuvant systemic chemotherapy schedules. One patient experienced disease recurrence in the liver 16 months after surgery. The remaining 9 patients have been well controlled by chemotherapy and/or observation during the follow-up period of 4 to 39 months after surgery. CONCLUSION: Intraoperative IP chemotherapy with cisplatin during surgical procedures is considered feasible for the treatment of primary epithelial ovarian cancer. Further studies, including long-term, prospective and comparative trials, are needed to validate the efficacy of this combined therapy. Korean Society of Gynecologic Oncology and Colposcopy 2012-04 2012-04-03 /pmc/articles/PMC3325355/ /pubmed/22523624 http://dx.doi.org/10.3802/jgo.2012.23.2.91 Text en Copyright © 2012. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Myung Joo
Jung, Yong Wook
Seong, Seok Ju
Yoon, Bo Sung
Kim, Mi La
Joo, Won Deok
Song, Tae Jong
Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer
title Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer
title_full Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer
title_fullStr Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer
title_full_unstemmed Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer
title_short Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer
title_sort intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325355/
https://www.ncbi.nlm.nih.gov/pubmed/22523624
http://dx.doi.org/10.3802/jgo.2012.23.2.91
work_keys_str_mv AT kimmyungjoo intraoperativeintraperitonealchemotherapywithcisplatininepithelialovariancancer
AT jungyongwook intraoperativeintraperitonealchemotherapywithcisplatininepithelialovariancancer
AT seongseokju intraoperativeintraperitonealchemotherapywithcisplatininepithelialovariancancer
AT yoonbosung intraoperativeintraperitonealchemotherapywithcisplatininepithelialovariancancer
AT kimmila intraoperativeintraperitonealchemotherapywithcisplatininepithelialovariancancer
AT joowondeok intraoperativeintraperitonealchemotherapywithcisplatininepithelialovariancancer
AT songtaejong intraoperativeintraperitonealchemotherapywithcisplatininepithelialovariancancer